Nitro (Nitroglycerin)

Quick links to important sections

Nitro (Nitroglycerin)

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitro (Nitroglycerin)

Property Description
Active Ingredient Nitroglycerin (Glyceryl trinitrate, GTN)
Primary Forms Sublingual tablet, Translingual spray, Transdermal patch
Pharmacological Class Vasodilator; Organic Nitrate
General Purpose To reduce cardiac workload by improving blood flow
Origin Synthetic Compound

What Type of Medicine is Nitroglycerin (Glyceryl Trinitrate)?

Nitroglycerin, officially known by its International Nonproprietary Name (INN) as Glyceryl trinitrate (GTN), is a powerful, synthetic medication classified as a Vasodilator within the Organic Nitrate pharmacological class. Its fundamental therapeutic purpose is to quickly adjust circulatory dynamics. This action improves the balance between the heart muscle's oxygen supply and its immediate demand.

As an organic nitrate, its core action involves functioning as an efficient precursor to nitric oxide (NO) within the body. This conversion triggers the rapid relaxation and widening, or vasodilation, of vascular smooth muscle, which reduces the effort required by the heart to pump blood.


Forms and Composition: Delivering the Active Ingredient

Nitroglycerin is prepared as a single active ingredient product across a variety of dosage forms tailored for different delivery needs. The main forms include rapid-acting sublingual tablets and translingual sprays, as well as continuous-release transdermal patches. The core component, Nitroglycerin, is blended with various bases or vehicles. This variety is a key feature, allowing physicians to select between an acute, immediate-response route, such as the spray, or a chronic, preventative support route, like the patch.

How Nitroglycerin Differs from Other Related Drugs

Nitroglycerin is clinically distinguished from other longer-acting Organic Nitrates, such as Isosorbide mononitrate, due to its characteristically rapid onset of action when administered through the mouth (sublingually or translingually). This superior speed is a crucial differentiating feature that positions Nitroglycerin as the primary nitrate used for immediate response.

What side effects are possible with Nitro (Nitroglycerin)?

Possible Side Effects and Safety Information

The safety profile of Nitroglycerin is primarily shaped by its potent vasodilating action, which affects the vascular and nervous systems, as detailed in regulatory documents.

Frequency-Classified Adverse Reactions

The official prescribing information categorizes adverse reactions based on their documented frequency:

  • Very Common: Headache, which is often severe, dose-related, and most prominent at the initiation of treatment.
  • Common: Dizziness, Hypotension (low blood pressure), Postural Hypotension (dizziness upon standing), Nausea, Vomiting, Flushing (cutaneous vasodilation), and Reflex Tachycardia (increased heart rate).

These effects related to vascular changes typically dominate the initial experience with the medicine.

Serious Adverse Reactions and Safety Constraints

Official labeling documents specific serious adverse reactions that are rare but clinically significant, including Severe Hypotension (which may lead to shock and collapse), Syncope (fainting), and the rare risk of Methemoglobinemia.

Strict safety constraints are defined, with the most critical being the absolute Contraindication of using Nitroglycerin concurrently with Phosphodiesterase Type 5 (PDE5) inhibitors (e.g., sildenafil). This restriction is in place due to the risk of dangerous, life-threatening hypotension.

Safety notes for specific populations include an increased risk of hypotension and postural hypotension observed in older adults. Furthermore, the official documents state that the medicine should not be used in individuals with conditions such as Severe Anemia or Increased Intracranial Pressure.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Nitroglycerin is characterized by signs of severe and persistent vasodilation, resulting in profound hemodynamic instability. Documented manifestations include severe hypotension, a persistent throbbing headache, vertigo, syncope (collapse), nausea, vomiting, and flushing which may progress to cold and cyanotic skin. Severe outcomes described in regulatory documents include circulatory collapse, increased intracranial pressure, and serious neurological events such as coma or paralysis.

A distinct, dose-related complication is Methemoglobinemia, a condition of impaired oxygen transport. For any suspected overdose, immediate contact with a healthcare practitioner or Poison Control Centre is required. Urgent medical attention must be sought if chest pain is not relieved and persists after a total of three doses (e.g., tablets or sprays) within a 15-minute period.

Management is directed toward increasing the central fluid volume to counteract hypotension, often via measures like passive elevation of the legs or intravenous fluid infusion. No specific antagonist for the vasodilator effect is known, but methylene blue is the recommended treatment for documented Methemoglobinemia. Continuous monitoring of blood pressure and heart rate is necessary, and caution is warranted for volume expansion in patients with renal disease.

Therapeutic Uses of Nitro (Nitroglycerin)

What Nitro (Nitroglycerin) Treats: Main Uses and Benefits

Nitroglycerin is commonly used for managing acute chest pain and providing supportive relief in specific cardiac contexts. Its primary role is to address symptoms related to physical discomfort arising from conditions characterized by periods of heightened symptoms. This includes managing Angina Pectoris (stable and unstable), supporting patients during episodes of Acute Coronary Syndrome (ACS), and easing manifestations of acute conditions like Pulmonary Edema or Acute Heart Failure.

The medication is applied across domains where additional symptomatic support is needed, particularly when groups of symptoms appear suddenly or fluctuate. Supportive relief generally helps patients cope more steadily with these difficult manifestations. It is also relevant when used before engaging in physical activity or stressful situations known to provoke pain, assisting with maintaining functional stability and contributing to improved comfort during symptomatic periods.

“This medication is commonly used to help manage the acute pressure that is characteristic of heart-related discomfort.”


Quick Fact: Relief for Acute Chest Discomfort

The medication is used for managing acute episodes of cardiac pain or is applied in addressing predictable, effort-related symptoms, contributing to easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The official eligibility profile for Nitroglycerin (Nitro) is strictly defined by regulatory documents, establishing clear patient populations who must not use the medicine and those whose use requires specific caution.

Use is contraindicated (absolutely prohibited) for patients with known hypersensitivity to nitrates and those who have recently taken Phosphodiesterase type 5 (PDE-5) inhibitors (such as sildenafil or tadalafil) or the soluble guanylate cyclase stimulator Riociguat. It is also prohibited in cases of severe anemia, marked hypotension or circulatory failure, and specific cardiac structural conditions like restrictive cardiomyopathy or significant aortic stenosis.

Safety and effectiveness are not established for pediatric patients (under 18 years old); therefore, use is not generally recommended in this age group. Use is established for adults and the geriatric population, though older adults may show increased sensitivity to hypotensive effects.

Use requires caution in specific populations, including pregnant women (where use is permitted only if clearly needed) and patients with hepatic or severe renal impairment or volume depletion.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This profile details the officially documented interaction patterns for Nitroglycerin (organic nitrate class), based strictly on authoritative government regulatory sources.


Interaction Scope

Detail Entities and Official Statements (Strictly Regulatory)
Medicinal product categories with documented interactions Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Antihypertensives, Ergot Alkaloids, Thrombolytic Agents, Anticoagulants.
Specific interacting medicines (if explicitly listed) Sildenafil, Tadalafil, Vardenafil, Riociguat, Aspirin, Heparin (IV), Alteplase (IV).
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic (PD) Interaction: Additive vasodilation resulting in profound hypotension. Pharmacokinetic (PK) Interaction: Decreased first-pass metabolism of co-administered drug leading to increased oral bioavailability.
Timing-based interaction rules (if applicable) Mandatory separation: 48 hours following Tadalafil administration; 24 hours following Sildenafil or Vardenafil administration (SmPC-based restriction).
Interaction-related restrictions Co-administration with all PDE-5 Inhibitors and Soluble Guanylate Cyclase Stimulators (Riociguat) is strictly contraindicated. Concomitant use with Alcohol (Ethanol) may increase the risk of hypotension.

Resulting Interaction Structure

Official Interaction Statements:

  • Co-administration with Phosphodiesterase-5 Inhibitors and Soluble Guanylate Cyclase Stimulators is contraindicated due to the potentiation of hypotensive effects.
  • Oral Nitroglycerin increases the oral bioavailability and blood levels of Ergot Alkaloids by decreasing their first-pass metabolism.
  • Concomitant use with Antihypertensives or Phenothiazines may result in additive hypotensive effects.
  • Administration with Intravenous Heparin reduces its anticoagulant effect, necessitating the monitoring of Activated Partial Thromboplastin Times (APTT).
  • Co-administration with Intravenous Alteplase has been documented to decrease its thrombolytic effect.

Regulatory documents define the product’s interaction structure primarily through two domains: absolute contraindication with vasodilatory agents due to severe pharmacodynamic reinforcement, and exposure modification of co-administered drugs. The profile requires explicit timing rules for administration separation to mitigate the risk of contraindicated combinations.

Mechanism of Action

How Nitro (Nitroglycerin) Works: The Mechanism of Action

Nitroglycerin functions as a prodrug, undergoing enzymatic biotransformation primarily by Aldehyde Dehydrogenase 2 (ALDH2) within vascular smooth muscle cells. This reaction releases the active intermediate, nitric oxide (NO). NO acts as a signaling molecule, binding to and activating soluble guanylate cyclase (sGC).

Activated sGC increases the concentration of the second messenger cyclic guanosine monophosphate (cGMP). Elevated cGMP activates protein kinases, initiating a cascade that results in the dephosphorylation of the myosin light chain and subsequent relaxation of the smooth muscle fibers (vasodilation).

This widespread vasodilation is most pronounced in venous capacitance vessels (venodilation). This physiological change reduces the volume of blood returning to the heart (preload) and decreases the pressure load (afterload) encountered during cardiac ejection. The resultant mechanical reduction in volume and pressure causes a decrease in myocardial wall tension, a factor correlated with cardiac oxygen consumption.

Dosage and Administration Information

Nitroglycerin is administered through several officially approved routes, including sublingual (tablet, powder), translingual (spray), transdermal (patch, ointment), oral extended-release capsules, and intravenous infusion. The official usage is defined by two primary patterns: intermittent and maintenance.

For acute, intermittent use of the sublingual or translingual forms, a single unit dose is taken at symptom onset. The dose may be repeated every five minutes, but label instructions strictly specify that a total of three doses must not be exceeded within a 15-minute period. Administration of sublingual forms requires the dose to be taken at rest, preferably in a sitting position. The tablet or powder must be allowed to dissolve entirely under the tongue or in the mouth without being swallowed or chewed.

For long-term, maintenance therapy, a cyclic dosing schedule is essential. This regimen mandates a daily 10- to 12-hour period free of the medication to prevent the development of pharmacological tolerance, which is a key structural component of its official use. Regarding scheduled regimens, if a maintenance dose is missed, patients are generally advised to take the dose when remembered, but skip the dose if it is near the time for the next scheduled dose, then resume the regular pattern. Furthermore, guidelines advise caution in older adults, where dosing typically starts at the low end of the official range, and abrupt withdrawal from long-term therapy is discouraged.

Recent Clinical Evidence

Nitro (Nitroglycerin): Recent Clinical Evidence

Overview of Nitroglycerin Use

Nitroglycerin is a nitrate that has been used historically for the treatment and prevention of angina pectoris (chest pain caused by reduced blood flow to the heart). Its primary action involves relaxing smooth muscle in the walls of blood vessels, leading to vasodilation (widening of vessels) and increased blood flow.

Key Research Findings

Clinical studies consistently demonstrate nitroglycerin's ability to rapidly alleviate acute anginal attacks when administered sublingually (under the tongue). This fast onset of action is attributed to its direct effect on vascular smooth muscle.

Research has also focused on comparing different formulations and routes of administration, including transdermal patches and oral sustained-release products, which are often studied for their role in prophylaxis (prevention) of chronic, stable angina.

Study Focus Key Observation
Acute Angina Relief Sublingual administration is associated with the fastest onset of relief.
Tolerance Development Continuous, high-dose therapy may lead to diminished effectiveness over time (tolerance), suggesting the need for nitrate-free intervals in prolonged treatment regimens.
Heart Failure (Acute) Intravenous nitroglycerin has been explored for its use in managing acute decompensated heart failure due to its potent preload reduction effects.

Current Research Directions

While the efficacy of nitroglycerin in treating angina is well-established, ongoing research continues to explore its optimal role in combination therapies and in managing complications of acute coronary syndromes. Studies emphasize the importance of appropriate dosing and administration to mitigate the development of nitrate tolerance and manage common side effects, such as headache and hypotension.

Key Studies & References Nitroglycerin (Rx) DailyMed Label - U.S. National Library of Medicine

Frequently Asked Questions (FAQ)

Common questions about Nitro (Nitroglycerin) (FAQ)


Q: How long does the effect of a nitroglycerin tablet last?

A: The rapid-acting forms of nitroglycerin, such as the sublingual tablet or translingual spray, are indicated for acute relief of chest pain. According to official administration instructions, a dose may be repeated approximately every five minutes if needed, up to a maximum of three doses in 15 minutes. This timeframe relates to the duration of the intended acute anginal relief.


Q: What happens if you accidentally swallow a sublingual nitroglycerin tablet?

A: Official directions strictly specify that sublingual tablets are designed to dissolve under the tongue for rapid absorption and should not be swallowed or chewed. When the dose is absorbed sublingually, the active ingredient enters the bloodstream quickly. If the tablet is accidentally swallowed, it may be broken down differently in the stomach, potentially resulting in a slower or less predictable effect.


Q: Is the sensation of burning under the tongue normal for a sublingual tablet?

A: Official product information states that some individuals may experience a burning or tingling sensation when the nitroglycerin tablet is placed under the tongue. This sensation may or may not occur, but its presence is not considered a dependable indicator of the tablet's full strength or potency.


Q: What happens if the nitroglycerin tablet doesn't tingle or burn under the tongue?

A: Experiencing a tingling or burning sensation under the tongue is not required to confirm that the nitroglycerin tablet is potent. The official label notes that this sensation is not a reliable method for determining the tablet’s strength. If the expected effect of relieving chest pain does not occur, the official label outlines the maximum number of times the dose may be repeated in a specific timeframe.


Q: What is a nitrate tolerance, and how does it relate to nitroglycerin?

A: Nitrate tolerance is a condition described in regulatory documents where the drug's effect lessens over time with continuous or excessive use. This development can cause the medicine to become less effective. To help minimize the risk of tolerance in long-term therapy, maintenance regimens typically incorporate a specific daily period free of the medication.


Q: Can nitroglycerin be used to prevent chest pain?

A: Yes, nitroglycerin is indicated for both the relief and the prevention (prophylaxis) of chest pain, depending on the form utilized. Rapid-acting forms can be taken 5 to 10 minutes before anticipated physical activities that might trigger an acute anginal attack. Longer-acting forms, like transdermal patches or extended-release capsules, are typically used for scheduled prevention of chronic angina.


Q: Is it safe to drink alcohol when using nitroglycerin?

A: Official drug interaction warnings state that using alcohol (Ethanol) while concurrently taking nitroglycerin may increase the risk of developing hypotension, which is a significant drop in blood pressure. This potential additive effect is related to both substances having blood pressure lowering properties.


Q: Is nitroglycerin the same thing as dynamite?

A: The active chemical compound in the medicine shares the same name as the ingredient used to create explosives. However, the medicine is formulated and administered in extremely small, carefully measured therapeutic doses for medical use. This is chemically distinct from the concentrated, stabilized formulations used in explosives.


Q: Why is it important to sit down when taking nitroglycerin?

A: Official product information advises that the rapid-acting forms of nitroglycerin should be taken while the patient is sitting down. The drug works by quickly lowering blood pressure, and this effect can cause dizziness or lightheadedness, known as postural hypotension. Taking the medicine while seated is intended to help reduce the risk of fainting or falling due to this rapid drop in pressure.


Q: Are there any specific concerns for women using nitroglycerin?

A: Regulatory information addresses use during pregnancy and breastfeeding. It states that the drug should only be used in pregnant women if clearly needed, as data on drug-related risk are limited. For nursing mothers, it is officially unknown if the drug is passed into human milk, leading to general caution for this population.


Q: Can someone who has had a stroke use nitroglycerin?

A: The official label lists increased intracranial pressure (ICP) as a condition that may require caution or prohibit use. This is because the medicine can potentially increase pressure inside the head. Use in patients with conditions associated with elevated ICP is therefore subject to specific safety consideration.


Q: Does the brand name of nitroglycerin matter, or is generic the same?

A: The active ingredient in all approved generic and brand-name nitroglycerin products is chemically the same compound. Generic medications approved by regulatory authorities must meet the same rigorous quality, strength, purity, and potency standards as the original brand-name drug.


Q: Is nitroglycerin treatment usually long-term or short-term?

A: Nitroglycerin is officially indicated for both acute (short-term) treatment and chronic (long-term) prevention. Short-term relief involves using sublingual tablets or spray as needed for acute pain. Long-term treatment typically uses maintenance forms like transdermal patches or capsules on a scheduled basis to prevent angina.


Q: Does nitroglycerin help with shortness of breath?

A: The primary official purpose of nitroglycerin is the relief and prevention of chest pain (angina). While the drug’s vasodilating effects have been examined in hospital settings for conditions that may cause shortness of breath, such as acute heart failure, this is generally not an officially stated primary indication for the forms prescribed for home management of angina.


Q: Why is nitroglycerin stored in special glass bottles?

A: Official storage instructions require that sublingual nitroglycerin tablets must be kept in their original, tightly-capped glass container. The specific container material and design are necessary to protect the medicine from environmental factors such as moisture, light, and heat, which can cause the highly volatile compound to degrade and lose its strength.


Q: Can people who are allergic to certain dyes still use nitroglycerin?

A: The official product information lists a contraindication for patients with known hypersensitivity (severe allergy) to nitroglycerin itself or any of the inactive ingredients, also called excipients, in the formulation. Patients with known allergies to dyes or other components should review the full ingredient list listed on the official label.

How should Nitro (Nitroglycerin) be stored and disposed of?

How to Store and Dispose of Nitroglycerin

Official labeling requires nitroglycerin to be stored strictly according to formulation to maintain potency.

Storage Requirements

  • Temperature and Protection: Sublingual tablets must be stored at Controlled Room Temperature (20 C to 25 C). All forms require protection from moisture, light, and excessive heat; the spray should not be frozen.
  • Container Rules: Sublingual tablets must remain in the original glass bottle with the cap tightly screwed on after each use. No other medications should be stored in this bottle.
  • Stability: Tablets may need to be discarded six months after the bottle is opened to ensure full strength. The translingual spray must be kept upright and primed before first use.
  • Child Safety: All nitroglycerin products must be stored out of the sight and reach of children.

Disposal Instructions

  • Unused or expired product should be disposed of by following local pharmaceutical waste regulations or by asking a pharmacist for guidance.
  • Do not incinerate or forcefully open the flammable spray container, even when empty. Patches should be folded adhesive-to-adhesive before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitro (Nitroglycerin) found in:

A-Z Index: